There are clinics hypothesis that systemic hypothermia (&le;34.9) could reduce infarct size if set before reperfusion. Peritoneal lavage had a well-established safety profile and given the large surface area of the bowel may cause rapid hypothermia reducing infarct size. The aim of this study was to evaluate the safety and efficacy of hypothermia induced by<a href="https://solaci.org/en/2015/06/24/velocity-peritoneal-hypothermia-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2: 1 (Absorb / Xience) with de novo lesions in native coronary arteries with a reference diameter between 2.25 and 3.8 mm estimated by quantitative angiography. All the patients underwent IVUS and<a href="https://solaci.org/en/2015/06/24/absorb-2-results-at-one-year-of-bioabsorbable-platform-versus-xience/" title="Read more" >...</a>

This study included 201 patients suffering ST-segment elevation acute coronary syndrome and randomized to the use of optical coherence tomography (OCT) versus conventional angiography for the procedure. OCT-guided group used more stents per patient (1.4 versus 1.2, p = 0.03) and greater release pressure. During control OCT suboptimal results were found in a third of<a href="https://solaci.org/en/2015/06/24/oct-stemi-primary-angioplasty-guided-by-oct/" title="Read more" >...</a>

This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5 years were included. The rate of target lesion (composite of cardiac death, myocardial infarction and target lesion revascularization) was 3.9% at one year and 5.1% at 2 years. Long-term clinical performance<a href="https://solaci.org/en/2015/06/24/nobori-ii-final-5-year-results-of-drug-eluting-stent-with-bio-absorbable-polymer/" title="Read more" >...</a>

Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom<a href="https://solaci.org/en/2015/06/24/titan-ami-final-results-of-bio-active-coated-stent/" title="Read more" >...</a>

This study randomized 2:1 &#8211; 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and<a href="https://solaci.org/en/2015/06/24/compare-ii-biolimus-eluting-stent-with-biodegradable-polymer-versus-everolimus-at-3-years/" title="Read more" >...</a>

The PARIS registry was a prospective observational study in 5018 patients undergoing coronary angioplasty with stent implantation in 15 centers. Three categories were prespecified in the discontinuation of dual antiplatelet therapy: 1) discontinuation for medical guidance, 2) transient discontinuation for less than 15 days for surgery and 3) permanent abandonment of it by non-adherence or<a href="https://solaci.org/en/2015/06/24/paris-register-non-adherence-impact-to-antiplatelet-therapy-among-men-and-women/" title="Read more" >...</a>

This paper included 5 studies that randomized patients to conventional stent versus chromium cobalt everolimus eluting stent; at 2 years, a significantly lower risk of cardiac death (2.7% for the everolimus eluting stent versus 4% for conventional stent, p = 0013) was observed. Myocardial infarction was reduced by over 80% with drug-eluting stent (0.08% versus<a href="https://solaci.org/en/2015/06/24/meta-analysis-confirms-the-reduction-in-ischemic-events-with-2nd-generation-des-versus-bms/" title="Read more" >...</a>

The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two<a href="https://solaci.org/en/2015/06/24/dessolve-ii-2-year-results-show-the-superiority-of-the-sirolimus-eluting-stent-with-fast-bio-absorbable-polymer/" title="Read more" >...</a>

The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with &nbsp;biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and &nbsp;the new device reached the non-inferiority with a MACE rate of 11.2% for<a href="https://solaci.org/en/2015/06/24/sort-out-v-similar-results-of-biolimus-eluting-stent-with-biodegradable-polymer-versus-sirolimus-eluting-stent-with-permanent-polymer/" title="Read more" >...</a>